CXCR7 signaling induced epithelial–mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas

详细信息    查看全文

• 作者：Hao Yu ; Linlin Zhang ; Peishu Liu
• 关键词：CXCR7 ; EMT ; AKT ; ERK ; Epithelial ovarian carcinomas
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1679-1683
• 全文大小：448 KB
• 参考文献：1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;S0140-736:62146-.
  2. Harter, P, Hilpert, F, Mahner, S, Heitz, F, Pfisterer, J, Bois, A (2010) Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 10: pp. 81-8 CrossRef
  3. Burger, RA, Brady, MF, Bookman, MA, Fleming, GF, Monk, BJ, Huang, H (2011) Gynecologic Oncology Group Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: pp. 2473-83 CrossRef
  4. Perren, TJ, Swart, AM, Pfisterer, J, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: pp. 2484-96 CrossRef
  5. Moustakas, A, Heldin, P (1840) TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta 2014: pp. 2621-34
  6. Lamouille, S, Xu, J, Derynck, R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: pp. 178-96 CrossRef
  7. Nieto, MA (2013) Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342: pp. 1234850 CrossRef
  8. Li, Y, Ma, J, Qian, X, Wu, Q, Xia, J, Miele, L (2013) Regulation of EMT by Notch signaling pathway in tumor progression. Curr Cancer Drug Targets 13: pp. 957-62 CrossRef
  9. Balogh, P, Katz, S, Kiss, AL (2013) The role of endocytic pathways in TGF-β signaling. Pathol Oncol Res 19: pp. 141-8 CrossRef
  10. Fuxe, J, Karlsson, MC (2012) TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22: pp. 455-61 CrossRef
  11. Gao, D, Vahdat, LT, Wong, S, Chang, JC, Mittal, V (2012) Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 72: pp. 4883-9 CrossRef
  12. Dave, B, Mittal, V, Tan, NM, Chang, JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14: pp. 202 CrossRef
  13. Roy, I, Evans, DB, Dwinell, MB (2014) Chemokines and chemokine receptors: update on utility and challenges for the clinician. Surgery 155: pp. 961-73 CrossRef
  14. Yoshie, O (2013) Chemokine receptors as therapeutic targets. Nihon Rinsho Meneki Gakkai Kaishi 36: pp. 189-96 CrossRef
  15. Ding, Y, Shimada, Y, Maeda, M, Kawabe, A, Kaganoi, J, Komoto, I (2003) Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 9: pp. 3406-12
  16. Takanami, I (2003) Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 105: pp. 186-9 CrossRef
  17. Wang, J, Xi, L, Hunt, JL, Gooding, W, Whiteside, TL, Chen, Z (2004) Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res 64: pp. 1861-6 CrossRef
  18. Müller, A, Homey, B, Soto, H, Ge, N, Catron, D, Buchanan, ME (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: pp. 50-6 CrossRef
  19. Aliaga, JC, Deschênes, C, Beaulieu, JF, Calvo, EL, Rivard, N (1999) Requirement of the MAP kinase cascade for c
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Epithelial–mesenchymal transition (EMT) plays an important role in oncogenesis, through which cancer cells acquire an invasion and metastasis capacity. Notably, the chemokine receptor CXCR7 and its ligands CCL19 can also facilitate lymph node metastasis in epithelial ovarian carcinomas. Here, we assumed that CXCR7 might be involved in the EMT process of epithelial ovarian carcinomas. In our study, CXCR7 activation and inhibition in SKOV3 were induced with exogenous CCL19 and CXCR7 small interfering RNA (CXCR7 siRNA), respectively. AKT and ERK protein of CXCR7 pathways as well as biomarkers (vimentin, snail, N-cadherin, and E-cadherin) of EMT were detected using the Western blot. Our results showed that CCL19 can induce AKT and ERK phosphorylation in a dose-dependent fashion; however, CXCR7 siRNA efficaciously suppressed CCL19-induced AKT and ERK phosphorylation in comparison with control siRNA. Importantly, CCL19 alone treatment can upregulate the expression of vimentin, snail, and N-cadherin of SKOV3 and downregulate the expression of E-cadherin. Conversely, knockdown of CXCR7 did not reveal any changes compared with CCL19 and the control. In conclusion, these findings demonstrate that EMT can be regulated by the CCL19/CXCR7 axis in epithelial ovarian carcinomas and then involved in the tumor cell invasion and metastasis process via activation of AKT and ERK pathways. Our study lays a new foundation for the treatment of epithelial ovarian carcinomas through antagonizing CXCR7.